Triptans in the Italian population: A drug utilization study and a literature review

Journal of Headache and Pain

Volumn 9, Issue 2, 2008, Pages 71-76

  Panconesi, Alessandro ^a   Pavone, Eleonora ^a   Vacca, Franca ^a   Vaiani, Monica ^a   Banfi, Roberto ^a  

^a NONE

Author keywords

Literature review; Prescription data; Triptan abusers; Triptans; Usage patterns

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; ELETRIPTAN; FLOVATRIPTAN; NOSE SPRAY; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CONTROLLED STUDY; DRUG ABUSE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG USE; DRUG UTILIZATION; FEMALE; HEADACHE; HEALTH INSURANCE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SUPPOSITORY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; ITALY; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; TRYPTAMINES;

EID: 41749093826     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-008-0020-3     Document Type: Review

References (33)

1. MacGregor EA, Brandes J, Eikermann A (2003) Migraine prevalence and treatment patterns: The global migraine and zolmitriptan evaluation survey. Headache 43:19-26
2. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF (2001) Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache 41:638-645
3. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 358:1668-1675
4. Panconesi A, Pavone E, Banfi R (2006) Triptan utilization patterns: A study based on patients prescription records of an Italian health authority in Tuscany. J Headache Pain 7:266-267 (abstract)
5. Pavone E, Banfi R, Vaiani M, Panconesi A (2007) Patterns of triptans use: A study based on the records of a community pharmaceutical department. Cephalalgia 27:1000-1004
6. Panconesi A, Pavone E, Vaiani M, Banfi R, Cinaglia I (2007) Pattern of triptans use in the population: Why the sub-utilization? Cephalalgia 27:741 (abstract)
7. Gaist D (1999) Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data. Cephalalgia 19:735-761
8. Etemad LR, Yang W, Globe D, Barlev A, Johnson KA (2005) Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm 11:137-144
9. Lohman JJHM, van der Kuy-de Ree MM (2005) Patterns of specific antimigraine drug use - a study based on the records of 18 community pharmacies. Cephalalgia 25:214-218
10. Perearnau P, Vuillemet F, Schick J, Weill G (2006) Patterns of prescription and usage of triptans in Alsace (France): Misuse is frequent and avoidable. Rev Neurol 162:347-357
11. Dekker F, Wiendels NJ, van der Vliet C, de Valk V, Knuistingh A, Ferrari MD, Assendelft WJJ (2007) Triptan use and overuse in the Netherlands, a national pharmaco-database analysis. Cephalgia 27:683 (abstract)
12. Ifergane G, Wirguin I, Shvartzman P (2006) Triptans - Why once? Headache 46:1261-1263
13. Lugardon S, Roussel H, Sciortino V, Montastruc JL, Lapeyre-Mestre M (2007) Triptan use and risk of cardiovascular events: A nested-case-control study from the French health system database. Eur J Clin Pharmacol 63:801-807
14. Sondergaard J, Foged A, Kragstrup J, Gaist D, Gram LF, Sindrup SH, Muckadell HUS, Larsen BO, Herborg H, Andersen M (2006) Intensive community pharmacy intervention had little impact on triptan consumption: A randomized controlled trial. Scand J Prim Health Care 24:16-21
15. Hoffman L, Mayzell G, Pedan A, Farrel M, Gilbert T (2003) Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray. J Manag Care Pharm 9:335-345
16. Lucas C, Auray J-P, Gaudin A-F, Dartigues J-F, Duru G, Henry P, Lanteri-Minet M, Pradalier A, Chazot G, El Hasnaoui A (2004) Use and misuse of triptans in France: Data from the GRIM2000 population survey. Cephalalgia 24:197-205
17. Lucas C, Chaffaut C, Artaz M-A, Lanteri-Minet M (2005) FRAMIG 2000: medical and therapeutic management of migraine in France. Cephalalgia 25:267-279
18. Williams D, Cahill T, Dowson A, Fearon H, Lipscombe S, O'Sullivan E, Rees T, Strang C, Valori A, Watson D (2002) Usage of triptans among migraine patients: An audit in nine GP practices. Curr Med Res Opin 18:1-9
19. Ferrari A, Pasciullo G, Savino G, Cicero AFG, Ottani A, Bertolini A, Sternieri E (2004) Headache treatment before and after the consultation of a specialized centre: A pharmacoepidemiology study. Cephalalgia 24:356-362
20. Jelinski SE, Becker WJ, Christie SN, Giammarco R, Mackie GF, Gawel MJ, Eloff AG, Magnusson JE (2006) Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada. Cephalalgia 26:578-588
21. Gaist D, Andersen M, Aarup AL, Hallas J, Gram LF (1997) Use of sumatriptan in Denmark in 1994-5: An epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 43:429-433
22. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts ACG (2003) Single use of sumatriptan: A patient interview study. Headache 43:109-116
23. Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S (2003) Coprescription of triptans with potentially interacting medications: A cohort study involving 240,268 patients. Headache 43:44-48
24. Visser WH, de Vriend RH, Jaspers MW, Ferrari MD (1996) Sumatriptan in clinical practice: A 2-year review of 453 migraine patients. Neurology 47:46-51
25. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC (2002) Features of medication overuse headache following overuse of different acute headache drugs. Neurology 59:1011-1014
26. Headache Classification Committee of the International Headache Society (2004) The international classification of headache disorders. Cephalagia 24(Suppl 1):1-160
27. Roussel H, Lo Re G, Honorat C, Alonso M, Sciortino V (2006) The use of triptan in ambulatory medicine in Midi-Pyrenees region: Clinical and pharmacological contra-indications and drug abuse. Therapie 61:507-516
28. Rahimtoola H, Egberts ACG, Buurma H, Tijssen CC, Leufkens HG (2001) Patterns of ergotamine and sumatriptan use in the Netherlands from 1991 to 1997. Cephalalgia 21:596-603
29. De Diego EV, Lanteri-Minet M (2005) Recognition and management of migraine in primary care: Influence of functional impact measured by the headache impact test (HIT). Cephalalgia 25:184-190
30. Nachit-Ouinekh F, Dartigues J-F, Chrysostome V, Henry P, Sourgen C, El Hasnaoui A (2005) Evolution of migraine after 10-year follow-up. Headache 45:1280-1287
31. Woeber C, Woeber-Bingoel C, Schmidt K, Zingerle R, Hattinger N, Hartl T, Zahlbruckner L, Boettcher A, Hanslik K, Aydinkoc K, Geuder E, Wessely P (2005) Symptomatology, impact and treatment of 6,000 headache attacks and episodes: The pamina study. Cephalalgia 25:646 (abstract)
32. Lygberg AC, Rasmussen BK, Jorgensen T, Jensen R (2005) Prognosis of migraine and tension-type headache: A population-based follow-up study. Neurology 65:580-585
33. Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C (2007) Satisfaction with current migraine therapy: Experience from three centers in US and Sweden. Headache 47:475-479